TXMD · Insider Trading
TherapeuticsMD, Inc.
Every open-market purchase and sale reported by TXMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-29 | Tommy G Thompson | Director | Buy | +8,400 | +$14.03K |
| 2025-11-05 | Marlan D Walker | Chief Executive Officer | A | +67,492 deriv. | — |
| 2025-11-05 | Gail K Naughton | Director | A | +8,500 deriv. | — |
| 2025-11-05 | Cooper C. Collins | Director | A | +8,500 deriv. | — |
| 2025-11-05 | Tommy G Thompson | Director | A | +8,500 deriv. | — |
| 2025-04-15 | Tommy G Thompson | Director | Buy | +325 | +$326 |
| 2025-04-15 | Marlan D Walker | Chief Executive Officer | Buy | +490 | +$489 |
| 2025-04-10 | Marlan D Walker | Chief Executive Officer | Buy | +2,303 | +$1.99K |
| 2025-02-20 | Marlan D Walker | Chief Executive Officer | M | +8,281 | — |
| 2025-02-20 | Tommy G Thompson | Director | M | +8,500 | — |
| 2025-02-20 | Cooper C. Collins | Director | M | +8,500 | — |
| 2025-02-20 | Gail K Naughton | Director | M | +8,500 | — |
| 2024-08-26 | Cooper C. Collins | Director | Buy | +4,094 | +$7.10K |
| 2024-08-23 | Cooper C. Collins | Director | Buy | +1,200 | +$2.04K |
| 2023-12-07 | Marlan D Walker | Chief Executive Officer | MIXED | +50,950 | −$43.68K |
| 2023-11-17 | David Efraim Rosen | 10%+ Owner | A | +1,754,384 | +$4.00M |
| 2023-08-21 | Joseph Ziegler | Principal Financial Officer | A | +7,500 | — |
| 2023-07-19 | Gail K Naughton | Director | A | +8,500 deriv. | — |
| 2023-07-19 | Tommy G Thompson | Director | A | +8,500 deriv. | — |
| 2023-07-19 | Cooper C. Collins | Director | A | +8,500 deriv. | — |
| 2023-06-29 | Rubric Capital Management LP | Director | A | +625,050 | +$2.30M |
| 2023-05-04 | Marlan D Walker | Chief Executive Officer | MIXED | +2,052 | −$2.52K |
| 2023-04-14 | Michael C Donegan | Prin. Fin. and Acctg. Officer | M | +50,000 | — |
| 2023-04-14 | Marlan D Walker | Chief Executive Officer | MIXED | +6,338 | −$4.28K |
| 2023-02-23 | Michael C Donegan | Prin. Fin. and Acctg. Officer | A | +50,000 deriv. | — |
| 2023-02-23 | Marlan D Walker | Chief Executive Officer | A | +70,000 deriv. | — |
| 2023-02-22 | David Efraim Rosen | Director | D | −58,000 | −$77.31M |
| 2023-01-30 | Michael C Donegan | Prin. Fin. and Acctg. Officer | MIXED | +4,243 | −$8.62K |
| 2023-01-25 | Michael C Donegan | Prin. Fin. and Acctg. Officer | MIXED | +3,056 | −$6.99K |
| 2023-01-03 | Rubric Capital Management LP | 10%+ Owner | Sell | −58,000 | −$77.31M |
| 2022-12-12 | Rubric Capital Management LP | 10%+ Owner | Buy | +29,650 | +$180.57K |
| 2022-12-09 | Mark A Glickman | Co-Chief Executive Officer | MIXED | +1,294 | −$2.17K |
| 2022-12-09 | Brian Bernick | Co-Chief Executive Officer | MIXED | +1,912 | −$6.62K |
| 2022-12-09 | Marlan D Walker | General Counsel | MIXED | +1,506 | −$5.18K |
| 2022-12-09 | Rubric Capital Management LP | 10%+ Owner | Buy | +40,826 | +$231.28K |
| 2022-12-09 | Michael C Donegan | Interim CFO/CAO/VP of Finance | MIXED | +2,566 | −$4.35K |
| 2022-12-08 | Gail K Naughton | Director | Sell | −3,922 | −$20.64K |
| 2022-10-31 | Rubric Capital Management LP | 10%+ Owner | Buy | +14,000 | +$14.00M |
| 2022-10-03 | Cooper C. Collins | Director | A | +5,000 deriv. | — |
| 2022-10-03 | Karen Ling | Director | A | +5,000 deriv. | — |
| 2022-10-03 | Gail K Naughton | Director | A | +5,000 deriv. | — |
| 2022-10-03 | Tommy G Thompson | Director | A | +34,175 deriv. | — |
| 2022-10-03 | Jules A. Musing | Director | A | +5,000 deriv. | — |
| 2022-10-03 | Rubric Capital Management LP | 10%+ Owner | Buy | +14,000 | +$14.00M |
| 2022-10-03 | Angus C. Russell | Director | A | +5,000 deriv. | — |
| 2022-10-03 | Paul Bisaro | Director | A | +5,000 deriv. | — |
| 2022-08-22 | Paul Bisaro | Director | M | +1,984 | — |
| 2022-08-22 | Karen Ling | Director | M | +1,984 | — |
| 2022-08-22 | Angus C. Russell | Director | M | +1,984 | — |
| 2022-08-22 | Cooper C. Collins | Director | M | +1,984 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Marlan D Walker | Chief Executive Officer | 73,639 | $132.55K |
| Cooper C. Collins | Director | 60,516 | $108.93K |
| Tommy G Thompson | Director | 37,491 | $67.48K |
| Gail K Naughton | Director | 8,500 | $15.30K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TXMD quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.